PeptiDream signs another big licensing deal, this one with Alnylam

31 July 2021

Japanese biotech PeptiDream (TYO: 4587) has entered into a license and collaboration agreement with US RNAi therapeutics company Alnylam Pharmaceuticals (Nasdaq: ALNY) to discover and develop peptide-siRNA conjugates to create multiple opportunities to deliver RNAi therapeutics to tissues outside the liver.

This comes hot on the heels of the news that PeptiDream has expanded its collaborations with fellow Japanese company Takeda (TYO: 4502) to create peptide-drug conjugates (PDCs) for several central nervous system (CNS) targets. PeptiDream is eligible to receive up to around $3.5 billion in total as upfront and potential contingent payments from this accord. Over the last few years, PeptiDream has entered into a string of collaborations, including with pharma giants Novartis (NOVN: VX) and Merck & Co (NYSE: MRK).

Through this latest collaboration, the companies will collaborate to select and optimize peptides for targeted delivery of small interfering RNA (siRNA) molecules to a wide range of cell types and tissues via specific interactions with receptors expressed on the target cells.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK